Vivesto AB ADR (OASMY)
OTHER OTC:OASMY
Top Page
Vivesto AB ADR
(OTC:OASMY)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.02
▲(70.00% Upside)
Action:ReiteratedDate:03/05/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and effectively zero recent revenue). Valuation signals are unreliable due to negative earnings and an unusually high reported dividend yield, while technical analysis is neutral because key indicators were not provided.
Positive Factors
Low leverage
A low debt-to-equity (~0.10) reduces fixed financing obligations and interest exposure, giving the company more financial flexibility to fund R&D or survive setbacks without immediate refinancing. This durability lowers bankruptcy risk during extended clinical timelines.
Negative Factors
Persistent unprofitability
Continued negative EBIT and operating cash flow erode shareholder capital, limit the firm's ability to self-fund trials or launches, and increase reliance on external financing. Over time this raises dilution and execution risk for a small biotech with long development cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A low debt-to-equity (~0.10) reduces fixed financing obligations and interest exposure, giving the company more financial flexibility to fund R&D or survive setbacks without immediate refinancing. This durability lowers bankruptcy risk during extended clinical timelines.
Read all positive factors
Vivesto AB ADR (OASMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.18M
Dividend YieldN/A
Average Volume (3M)105.00
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding369,045,620
10 Day Avg. Volume15
30 Day Avg. Volume105
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.03
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap5.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-64.70
Enterprise Value/Ebitda-2.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Vivesto AB ADR Business Overview & Revenue Model
Company Description
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio incl...
How the Company Makes Money
Vivesto AB’s revenue model is based on monetizing oncology drug assets through product commercialization and/or partnering. Potential revenue streams typically include (i) net sales from any marketed products the company commercializes itself, (ii...
Vivesto AB ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 6.61M | 1.01M | 26.19M |
| Gross Profit | 0.00 | 0.00 | 6.61M | -10.66M | -17.93M |
| EBITDA | -32.31M | -38.77M | -81.14M | -89.76M | -97.62M |
| Net Income | -32.04M | -39.75M | -128.74M | -367.03M | -138.94M |
Balance Sheet | |||||
| Total Assets | 149.04M | 172.88M | 220.67M | 355.88M | 594.31M |
| Cash, Cash Equivalents and Short-Term Investments | 2.10M | 32.29M | 77.04M | 142.51M | 97.27M |
| Total Debt | 13.00M | 0.00 | 0.00 | 8.17M | 10.43M |
| Total Liabilities | 24.46M | 14.55M | 22.87M | 30.45M | 44.59M |
| Stockholders Equity | 124.58M | 158.33M | 197.80M | 325.42M | 549.71M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -47.25M | -69.40M | -80.79M | -179.91M |
| Operating Cash Flow | -31.92M | -47.25M | -68.74M | -80.52M | -145.56M |
| Investing Cash Flow | 20.54M | 43.40M | 63.73M | -45.28M | 118.65M |
| Financing Cash Flow | 12.22M | 0.00 | 0.00 | 128.76M | -5.81M |
Vivesto AB ADR Risk Analysis
Vivesto AB ADR disclosed 67 risk factors in its most recent earnings report. Vivesto AB ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivesto AB ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $44.66M | -3.67 | -19.05% | ― | -65.77% | 38.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $9.18M | -0.10 | -22.76% | ― | ― | ― | |
46 Neutral | $23.96M | -33.14 | 0.27% | ― | 75.19% | ― | |
45 Neutral | $7.14M | -10.73 | -40.66% | ― | -1.50% | 80.17% | |
44 Neutral | $4.90M | -0.60 | -24.34% | ― | 13.24% | 98.80% | |
40 Underperform | $2.25M | -0.71 | -93.87% | ― | -0.74% | 81.49% |
* Healthcare Sector Average
OASMY
Vivesto AB ADR
0.02
0.00
0.00%
TXMD
TherapeuticsMD
2.07
1.04
100.97%
SCYX
SCYNEXIS
1.00
0.01
1.32%
YCBD
cbdMD
0.68
-1.24
-64.58%
SBFM
Sunshine Biopharma
1.00
-0.31
-23.82%
IMCC
IM Cannabis Corp
0.36
-1.01
-73.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.